Sage Journals: Discover world-class research

Open access

Review article

First published 2024

The Role of Antibody-Drug Conjugates in Urothelial Cancer: A Review of Recent Advances in the Treatment of Locally Advanced and Metastatic Urothelial Cancer

Evangelia Vlachou, Burles Avner Johnson, Jean Hoffman-Censits

Clinical Medicine Insights: Oncology

Retricted access

Case report

First published 2024-8

Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis

Harshit Khosla, Sita Bhatt, Ming-Jin Wang [...]

Journal of Oncology Pharmacy Practice

Open access

Case report

First published 2023-10

Drug extravasation with Enfortumab vedotin

Christopher Ryan Grant, Dimitri de Kouchkovsky, Arash Rezazadeh Kalebasty [...]

Journal of Oncology Pharmacy Practice

Open access

Review article

First published 2020

Enfortumab Vedotin in urothelial cancer

Marie Alt, Carlos Stecca, Swanee Tobin [...]

Therapeutic Advances in Urology

Retricted access

Review article

First published 2021-6

Enfortumab Vedotin-ejfv: A First-in-Class Anti–Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma

Zachery Halford, Mary Kate Anderson, Matthew D. Clark

Annals of Pharmacotherapy

Open access

Case report

First published 2024

Complete Pathologic Response With Pembrolizumab and Enfortumab Vedotin in Urothelial Carcinoma of the Upper Urinary Tract

Kok Hoe Chan, Tung Shu, Majd Al Shaarani [...]

Journal of Investigative Medicine High Impact Case Reports

Open access

Research article

First published 2026

Real-world use of enfortumab vedotin in metastatic urothelial carcinoma: efficacy,safety,and risk stratification

Martina Catalano, Sara Bartoli, Alessia Salfi [...]

Therapeutic Advances in Urology

Open access

Research article

First published 2025-1

Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma

Nobutaka Nishimura, Makito Miyake, Norimi Takamatsu [...]

Bladder Cancer

Open access

Research article

First published 2022

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma

Qiuji Wu, Yi Qin, Weiting Liao [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2025

Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis

Youwen Zhu, Kun Liu, Hong Zhu [...]

Therapeutic Advances in Medical Oncology

Search results